Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Italy
*Corresponding author: Roberto Castelli, Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Luigi Sacco Hospital Milan, Milan, Italy
Submission: October 26, 2017; Published: April 17, 2018
ISSN: 2578-0239Volume1 Issue3
Myelodys plastic syndromes (MDS) are heterogeneous clonal disorders ranging from indolent conditions with a near-normal life expectancy to forms approaching acute myeloid leukemia (AML). Comorbid conditions have rarely been systematically studied among patients with myelodysplastic syndromes. Older age per se has a negative impact on survival of MDS patients, in particular of those with lower risk.78. However, age indirectly affects also the survival of higher-risk patients by limiting their eligibility to intensive treatments. In addition, aging is associated with an increasingly high risk of developing comorbidity, and a high prevalence of co-morbid diseases has indeed been reported in MDS patients. Poly pharmacy and the impact of multi morbidities / comorbidities in patients with low risk MDS patients is poorly explored topic, thereby in this study we focused on medications, multi morbidities and comorbidities of 155 low risk MDS patients followed in our Haematological University Hospital.